A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes

202047 citationsJournal Articlehybrid Open Access

Authors

The study was funded by GlaxoSmithKline. Graphical abstract.

Good health and well-being

Published in: Diabetologia

Volume 64, Issue 2, pp. 313-324

Field-Weighted Citation Impact: 4.50